Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: HonorHealth Research Institute Clear all
Completed Not applicable Interventional Results available

Hair Loss Prevention Study for Pancreatic Cancer

NCT04492800
View directory record Official record
Conditions
Alopecia
Interventions
Paxman Scalp Cooling Device
Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Withdrawn Phase 1Phase 2 Interventional

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

NCT03908333
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Interventions
Ascorbic Acid, Paclitaxel protein-bound, Cisplatin, Gemcitabine
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • San Diego, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 29, 2026, 9:08 AM EDT
Terminated Phase 1 Interventional

The Seven Trial: Exploiting the Unfolded Protein Response

NCT06076837
View directory record Official record
Conditions
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions
Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Withdrawn Phase 1 Interventional

Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

NCT04611139
View directory record Official record
Conditions
SCCOHT, Ovarian Clear Cell Tumor, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer
Interventions
SP-2577, Pembrolizumab
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 29, 2026, 9:08 AM EDT
Terminated Phase 2 Interventional Results available

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

NCT03714555
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Safety Laboratories, AE Assessment, Physical Exam, Concomitant Medication Review, Tumor Imaging, nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate, FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate, Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
Diagnostic Test · Other · Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 105 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 29, 2026, 9:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

NCT07463599
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
Interventions
Tegavivint
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Terminated Phase 2 Interventional Results available

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

NCT04339426
View directory record Official record
Conditions
Covid19
Interventions
Atovaquone/Azithromycin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 95 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Not applicable Interventional

The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients

NCT04275830
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Bone Marrow Transplant, Heart Rate Variability, Autonomic Nervous System, Stress, Mood, Psychological Distress, Emotion Regulation, Communication Research, Narrative
Interventions
Baseline Surveys, Heart rate variability biofeedback, Heart rate variability waitlist and Digital storytelling Control intervention
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 22, 2022 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

NCT03138720
View directory record Official record
Conditions
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
Interventions
Paclitaxel Protein Bound (Abraxane)
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer

NCT04669197
View directory record Official record
Conditions
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Paclitaxel protein bound, Gemcitabine, Cisplatin, Hydroxychloroquine
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

NCT02754726
View directory record Official record
Conditions
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Nivolumab, Albumin-bound paclitaxel, Paricalcitol, Cisplatin, Gemcitabine
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

NCT03415854
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases, Adenocarcinoma
Interventions
Paricalcitol (Zemplar)
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

NCT03410030
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreas Metastases
Interventions
High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2, Gemcitabine 1000mg/m^2, High Dose Ascorbic Acid 37.5 g/m^2, High Dose Ascorbic Acid 56.25 g/m^2, High Dose Ascorbic Acid 75 g/m^2
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients

NCT04291066
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
N-Acetyl cysteine
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
60 Years to 100 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Withdrawn Phase 1Phase 2 Interventional

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

NCT03697239
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Interventions
Ascorbic Acid, Paclitaxel protein-bound, Cisplatin, Gemcitabine
Drug
Lead sponsor
Hitendra Patel
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Comparison of Phototherapy Using Neolight Skylife Versus Standardized Phototherapy for Hyperbilirubinemia in Newborns

NCT03599258
View directory record Official record
Conditions
Jaundice, Neonatal, Neonatal Hyperbilirubinemia, Neonatal Disorder
Interventions
Skylife, Standard Therapy
Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
0 Minutes to 7 Minutes
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 29, 2026, 9:08 AM EDT
Completed No phase listed Observational

Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer

NCT02790944
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Multi-gene Next Generation Sequencing Panel
Genetic
Lead sponsor
Ambry Genetics
Industry
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine

NCT05175521
View directory record Official record
Conditions
Migraine
Interventions
Eucalyptus Oil Scent, Isopropyl Alcohol Vapors
Other
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

NCT03915444
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
NabCG (nab-Paclitaxel + Cisplatin + Gemcitabine)
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 105 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • Miami, Florida • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 29, 2026, 9:08 AM EDT
Completed No phase listed Observational

A Standardized Bundle Protocol to Optimize Outcomes With Patients Undergoing Gynecological Surgery

NCT03610425
View directory record Official record
Conditions
Hysterectomy
Interventions
Not listed
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
Female only
Enrollment
50 participants
Timeline
2017 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 29, 2026, 9:08 AM EDT
Withdrawn Phase 2 Interventional

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

NCT05216120
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Pemigatinib 4.5 MG
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

NCT05004025
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Novocure Optune, Opdivo, Yervoy
Device · Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Scottsdale, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 29, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

NCT05229588
View directory record Official record
Conditions
Gastrointestinal Malignancies
Interventions
Lurbinectedin 4 MG Injection [Zepzelca]
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 29, 2026, 9:08 AM EDT